Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 86Colonic Neoplasms 32Rectal Neoplasms 31Neoplasms 24Pancreatic Neoplasms 22Stomach Neoplasms 20Neoplasm Metastasis 20Esophageal Neoplasms 20Neuroblastoma 12Glioma 11Sarcoma 9Glioblastoma 9Small Cell Lung Carcinoma 8Carcinoma, Non-Small-Cell Lung 8Brain Neoplasms 8Adenocarcinoma Of Esophagus 8Rhabdomyosarcoma 7Lung Neoplasms 7Sarcoma, Ewing 6Gliosarcoma 6Esophageal Squamous Cell Carcinoma 6Medulloblastoma 5Central Nervous System Neoplasms 5Breast Neoplasms 5Parkinson Disease 4, Autosomal Dominant Lewy Body 4Intestinal Neoplasms 4Gastrointestinal Neoplasms 4Digestive System Neoplasms 4Digestive System Diseases 4Adenocarcinoma 4

Interventions

Gemcitabine 13Cisplatin 8Capecitabine 8Fluorouracil 5pembrolizumab 4Oxaliplatin 4Sorafenib 3Leucovorin 3Erlotinib Hydrochloride 3trametinib 2regorafenib 2durvalumab 2N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine 2Magnetic Resonance Spectroscopy 2Lapatinib 2trifluridine tipiracil drug combination 1tremelimumab 1spartalizumab 1seribantumab 1olutasidenib 1olaparib 1devimistat 1derazantinib 1dehydroftorafur 1cediranib 1cabozantinib 1Trifluridine 1Trastuzumab 1Therapeutics 1Sutures 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Bile Duct Neoplasms × Irinotecan × Clear all
NCT04072445 2023-08-09

Trifluridine/Tipiracil and Irinotecan for the Treatment of Advanced Refractory Biliary Tract Cancer

Mayo Clinic

Phase 2 Completed
28 enrolled 20 charts
Gastrointestinal

Bile Duct Neoplasms, Gallbladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡